相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Correlation between serum galectin-9 levels and liver fibrosis
Koji Fujita et al.
JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY (2018)
Exosomal PD-L1 contributes to immunosuppression and is associated with anti-PD-1 response
Gang Chen et al.
NATURE (2018)
Clinical Significance of PD-L1+ Exosomes in Plasma of Head and Neck Cancer Patients
Marie-Nicole Theodoraki et al.
CLINICAL CANCER RESEARCH (2018)
Immune checkpoint molecules soluble program death ligand 1 and galectin-9 are increased in pregnancy
Elizabeth Ann L. Enninga et al.
AMERICAN JOURNAL OF REPRODUCTIVE IMMUNOLOGY (2018)
Antibodies Against Immune Checkpoint Molecules Restore Functions of Tumor-Infiltrating T Cells in Hepatocellular Carcinomas
Guoying Zhou et al.
GASTROENTEROLOGY (2017)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
Soluble PD-L1 as a Biomarker in Malignant Melanoma Treated with Checkpoint Blockade
Jun Zhou et al.
CANCER IMMUNOLOGY RESEARCH (2017)
Serum levels of soluble programmed death protein 1 (sPD-1) and soluble programmed death ligand 1 (sPD-L1) in advanced pancreatic cancer
Stephan Kruger et al.
ONCOIMMUNOLOGY (2017)
PD-L1, Galectin-9 and CD8+ tumor-infiltrating lymphocytes are associated with survival in hepatocellular carcinoma
Kostandinos Sideras et al.
ONCOIMMUNOLOGY (2017)
The increase of circulating PD-L1-expressing CD68+ macrophage in ovarian cancer
Qiu-Xia Qu et al.
TUMOR BIOLOGY (2016)
Discovery of TSR-022, a novel, potent anti-human TIM-3 therapeutic antibody
A. Murtaza et al.
EUROPEAN JOURNAL OF CANCER (2016)
High levels of the soluble programmed death-ligand (sPD-L1) identify hepatocellular carcinoma patients with a poor prognosis
Fabian Finkelmeier et al.
EUROPEAN JOURNAL OF CANCER (2016)
Frequent expression of PD-L1 on circulating breast cancer cells
Martine Mazel et al.
MOLECULAR ONCOLOGY (2015)
Pembrolizumab for the Treatment of Non-Small-Cell Lung Cancer
Edward B. Garon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Circulating PD-L1 in NSCLC patients and the correlation between the level of PD-L1 expression and the clinical characteristics
Jie Zhang et al.
THORACIC CANCER (2015)
PD-L1 Antibodies to Its Cytoplasmic Domain Most Clearly Delineate Cell Membranes in Immunohistochemical Staining of Tumor Cells
Kathleen M. Mahoney et al.
CANCER IMMUNOLOGY RESEARCH (2015)
Programmed death ligand-1 over-expression correlates with malignancy and contributes to immune regulation in ovarian cancer
Christian J. Maine et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2014)
Role of the immune system in pancreatic cancer progression and immune modulating treatment strategies
K. Sideras et al.
CANCER TREATMENT REVIEWS (2014)
Galectin-9-CD44 Interaction Enhances Stability and Function of Adaptive Regulatory T Cells
Chuan Wu et al.
IMMUNITY (2014)
Programmed death ligand-1 expression in non-small cell lung cancer
Vamsidhar Velcheti et al.
LABORATORY INVESTIGATION (2014)
High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-Cell lymphoma: results from a French multicenter clinical trial
D. Rossille et al.
LEUKEMIA (2014)
Therapeutic potential of Galectin-9 in human disease
Valerie R. Wiersma et al.
MEDICINAL RESEARCH REVIEWS (2013)
Up-Regulation of PD-L1, IDO, and Tregs in the Melanoma Tumor Microenvironment Is Driven by CD8+ T Cells
Stefani Spranger et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Serum galectin-9 levels are elevated in the patients with type 2 diabetes and chronic kidney disease
Yuko Kurose et al.
BMC NEPHROLOGY (2013)
Galectin-9 and IL-21 Mediate Cross-regulation between Th17 and Treg Cells during Acute Hepatitis C
Hassen Kared et al.
PLOS PATHOGENS (2013)
Galectin-9 Acts as a Prognostic Factor with Antimetastatic Potential in Hepatocellular Carcinoma
Zhao-Yang Zhang et al.
ASIAN PACIFIC JOURNAL OF CANCER PREVENTION (2012)
Upregulation of B7-H1 expression is associated with macrophage infiltration in hepatocellular carcinomas
Jie Chen et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Tim-3/galectin-9 signaling pathway mediates T-cell dysfunction and predicts poor prognosis in patients with hepatitis B virus-associated hepatocellular carcinoma
Hang Li et al.
HEPATOLOGY (2012)
Soluble B7-H1: Differences in production between dendritic cells and T cells
Xavier Frigola et al.
IMMUNOLOGY LETTERS (2012)
Activated CD69+ T Cells Foster Immune Privilege by Regulating IDO Expression in Tumor-Associated Macrophages
Qiyi Zhao et al.
JOURNAL OF IMMUNOLOGY (2012)
Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer
Suzanne L. Topalian et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Immunological and Molecular Correlates of Disease Recurrence after Liver Resection for Hepatocellular Carcinoma
Elisabetta Cariani et al.
PLOS ONE (2012)
Upregulation of the Tim-3/Galectin-9 Pathway of T Cell Exhaustion in Chronic Hepatitis B Virus Infection
Gaia Nebbia et al.
PLOS ONE (2012)
Colocalization of Inflammatory Response with B7-H1 Expression in Human Melanocytic Lesions Supports an Adaptive Resistance Mechanism of Immune Escape
Janis M. Taube et al.
SCIENCE TRANSLATIONAL MEDICINE (2012)
Global Cancer Statistics
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2011)
Identification of a Soluble Form of B7-H1 That Retains Immunosuppressive Activity and Is Associated with Aggressive Renal Cell Carcinoma
Xavier Frigola et al.
CLINICAL CANCER RESEARCH (2011)
Serum Galectin-2,-4, and -8 Are Greatly Increased in Colon and Breast Cancer Patients and Promote Cancer Cell Adhesion to Blood Vascular Endothelium
Hannah Barrow et al.
CLINICAL CANCER RESEARCH (2011)
Development of a sandwich ELISA for evaluating soluble PD-L1 (CD274) in human sera of different ages as well as supernatants of PD-L1+ cell lines
Yongjing Chen et al.
CYTOKINE (2011)
Interleukin-17-educated monocytes suppress cytotoxic T-cell function through B7-H1 in hepatocellular carcinoma patients
Qiyi Zhao et al.
EUROPEAN JOURNAL OF IMMUNOLOGY (2011)
Cancer immunotherapy comes of age
Ira Mellman et al.
NATURE (2011)
Upregulation of Tim-3 and PD-1 expression is associated with tumor antigen-specific CD8+ T cell dysfunction in melanoma patients
Julien Fourcade et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2010)
A Crucial Role for Kupffer Cell-Derived Galectin-9 in Regulation of T Cell Immunity in Hepatitis C Infection
John A. Mengshol et al.
PLOS ONE (2010)
Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells
Jihene Klibi et al.
BLOOD (2009)
Kupffer Cell Suppression of CD8+ T Cells in Human Hepatocellular Carcinoma Is Mediated by B7-H1/Programmed Death-1 Interactions
Ke Wu et al.
CANCER RESEARCH (2009)
Overexpression of PD-L1 Significantly Associates with Tumor Aggressiveness and Postoperative Recurrence in Human Hepatocellular Carcinoma
Qiang Gao et al.
CLINICAL CANCER RESEARCH (2009)
Diagnosis and treatment of hepatocellular carcinoma
Hashem B. El-Serag et al.
GASTROENTEROLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
PD-L1 is induced in hepatocytes by viral infection and by interferon-α and -γ and mediates T cell apoptosis
Marcus Muehlbauer et al.
JOURNAL OF HEPATOLOGY (2006)
Galectin-9 as a prognostic factor with antimetastatic potential in breast cancer
A Irie et al.
CLINICAL CANCER RESEARCH (2005)
Immunosuppressive networks in the tumour environment and their therapeutic relevance
WP Zou
NATURE REVIEWS CANCER (2005)
Possible role of galectin-9 in cell aggregation and apoptosis of human melanoma cell lines and its clinical significance
T Kageshita et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
分享论文
